Latest Publishing News

AnteoTech (ASX: ADO) pushed forward its advanced battery and life sciences technologies in the March 2026 quarter, achieving key product validations and expanding its sales pipeline to record levels. The company ended the period with A$3.3 million cash and no debt following a recent A$3.5 million capital raise.

The ASX has published its latest roster of over 40 entities suspended for more than three months, detailing looming deadlines for overdue reports and trading resumption plans. Failure to meet these could trigger removal from the official list.

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.

Nyrada has secured ethics approval to start its Phase IIa trial of Xolatryp in heart attack patients, with recruitment beginning in April 2026. The biotech also bolsters its cash position to AU$6.74 million and pursues new oncology indications.

African Gold Ltd shareholders and optionholders overwhelmingly approved schemes of arrangement to be acquired by Montage Gold Corp, setting the stage for a court approval hearing next week.

Vinyl Group has completed its $10.5 million acquisition of Val Morgan Digital, boosting its digital media revenue by 73% and audience reach to rival Australia's largest media players. The deal also brings HOYTS CEO Damian Keogh onto Vinyl’s board, signalling a strategic pivot towards integrated media offerings.

Sequoia Financial Group has provided an update on the proposed sale of InterPrac Financial Planning to Conquest Investment Partners, highlighting ASIC’s court action seeking receiver appointment over certain guarantees and ongoing discussions with ASX regarding shareholder approval.

Pacific Edge reported a 2.7% increase in test volumes for Q4 2026 despite operational challenges, supported by growing momentum toward Medicare coverage and expanded commercial payer adoption in the US and Asia Pacific.

PlaySide Studios Limited (ASX: PLY) has announced that its upcoming game MOUSE: P.I. For Hire has exceeded 1.5 million wishlists, surpassing previous guidance, ahead of its global digital launch on 16 April 2026. The company expects FY26 revenue to exceed FY25 with reduced operating costs.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals has broadened availability of DAYBUE STIX, a new FDA-approved powder formulation of trofinetide for Rett syndrome, in the US. Early caregiver feedback and expert consensus highlight its potential role in personalised patient care.

Sequoia Financial Group Ltd has admitted to unintentionally breaching ASX Listing Rule 15.7 after its CEO disclosed details of the InterPrac Financial Planning sale to a journalist during a trading halt. The company is reviewing its continuous disclosure practices to prevent future occurrences.

PolarX Limited has reported exceptional high-grade copper assay results from its 2025 drilling at the Caribou Dome Copper Project in Alaska, with plans for a substantial 10,500m drilling campaign commencing in June 2026.